First Trust Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

First Trust Advisors’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-147,788	Closed	-$1.55M	–	2498
2017 Q1	$1.55M	Buy	147,788 +75,817	+105%	+$808K	﹤0.01%	1645
2016 Q4	$662K	Buy	+71,971	New	+$813K	﹤0.01%	2001
2016 Q1	–	Sell	-13,216	Closed	-$378K	–	2333
2015 Q4	$378K	Sell	13,216 -258	-2%	-$7.15K	﹤0.01%	2035
2015 Q3	$383K	Sell	13,474 -640	-5%	-$23.6K	﹤0.01%	2034
2015 Q2	$507K	Sell	14,114 -612	-4%	-$19.1K	﹤0.01%	1986
2015 Q1	$428K	Buy	+14,726	New	+$389K	﹤0.01%	2006

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Trust Advisors's INSY Position: Q2 2017 in Review

First Trust Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 147,788 shares — an estimated $1.55M sold.

First Trust Advisors first reported a position in INSY in Q1 2015 and held it in 6 quarters. The position peaked at $1.55M in Q1 2017. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

First Trust Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
First Trust Advisors sold 147,788 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $1.55M.
First Trust Advisors first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
First Trust Advisors's Insys Therapeutics, Inc. position peaked at $1.55M in Q1 2017.
118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on First Trust Advisors's 13F filing for Q2 2017, filed 2 Aug 2017.